



# Pertuzumab




# TDM-1




OUTC\_COD

soc\_name

# Lapatinib




# Neratinib





# Tucatinib



# **Comparing The Difference of Adverse Events with HER2 Inhibitors: A Study of The FDA Adverse Event Reporting System (FAERS)**

## **Figure Legend**

**Supplementary Figure 1.** Mulberry diagram visualizing the correspondence of adverse events (soc\_name) and outcomes (OUTC\_COD) reported in cases treated with pertuzumab, TDM-1, lapatinib, neratinib, or tucatinib.